CEL-SCI Corporation (CVM) Reports Phase 3 Biomarker Data; Plans U.S. Registration Study

What happened

CEL-SCI reported new analyses from its completed Phase 3 Multikine study showing a biomarker-selected subgroup with 73.4% 5-year overall survival versus 45.0% for standard of care, and plans a 212-patient U.S. Registration Study with overall survival as the primary endpoint.

Confirmed

Global impact / market context

A large survival gap in selected patients could strengthen the case for approval and lift expectations for CEL-SCI. The planned 212-patient U.S. study defines the next catalyst, so investors now wait on early response data and regulatory feedback on possible acceleration.

Analyst inference

The data extend prior Phase 3 findings but focus on a biomarker-selected, pre-surgical group, which narrows the addressable patient pool. Because overall survival takes time to mature, nearer-term pre-surgical response and tumor shrinkage readouts carry much of the evidentiary weight.

Analyst inference

What to watch

1. CEL-SCI plans a 212-patient U.S. Registration Study using overall survival as the primary endpoint, which means the main measure is how long patients live, a slow readout. Proposed
2. Early pre-surgical response data, including higher reported response rates and tumor shrinkage before surgery, could shape whether regulators allow an accelerated path before survival data mature. Analyst inference
3. Regulatory feedback on potential acceleration and any cited favorable safety profile matter for adoption and payer uptake, which means insurers' willingness to cover treatment, affecting future revenue. Analyst inference

Evidence

• Original source link unavailable